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Abstract
During spring-summer 2009, several observational studies from Canada showed increased risk of medically-attended,
laboratory-confirmed A(H1N1)pdm09 illness among prior recipients of 2008–09 trivalent inactivated influenza vaccine (TIV).
Explanatory hypotheses included direct and indirect vaccine effects. In a randomized placebo-controlled ferret study, we
tested whether prior receipt of 2008–09 TIV may have directly influenced A(H1N1)pdm09 illness. Thirty-two ferrets (16/
group) received 0.5 mL intra-muscular injections of the Canadian-manufactured, commercially-available, non-adjuvanted,
split 2008–09 Fluviral or PBS placebo on days 0 and 28. On day 49 all animals were challenged (Ch0) with A(H1N1)pdm09.
Four ferrets per group were randomly selected for sacrifice at day 5 post-challenge (Ch+5) and the rest followed until Ch+14.
Sera were tested for antibody to vaccine antigens and A(H1N1)pdm09 by hemagglutination inhibition (HI),
microneutralization (MN), nucleoprotein-based ELISA and HA1-based microarray assays. Clinical characteristics and nasal
virus titers were recorded pre-challenge then post-challenge until sacrifice when lung virus titers, cytokines and
inflammatory scores were determined. Baseline characteristics were similar between the two groups of influenza-naı¨ve
animals. Antibody rise to vaccine antigens was evident by ELISA and HA1-based microarray but not by HI or MN assays; virus
challenge raised antibody to A(H1N1)pdm09 by all assays in both groups. Beginning at Ch+2, vaccinated animals
experienced greater loss of appetite and weight than placebo animals, reaching the greatest between-group difference in
weight loss relative to baseline at Ch+5 (7.4% vs. 5.2%; p = 0.01). At Ch+5 vaccinated animals had higher lung virus titers
(log-mean 4.96 vs. 4.23pfu/mL, respectively; p = 0.01), lung inflammatory scores (5.8 vs. 2.1, respectively; p = 0.051) and
cytokine levels (p.0.05). At Ch+14, both groups had recovered. Findings in influenza-naı¨ve, systematically-infected ferrets
may not replicate the human experience. While they cannot be considered conclusive to explain human observations, these
ferret findings are consistent with direct, adverse effect of prior 2008–09 TIV receipt on A(H1N1)pdm09 illness. As such, they
warrant further in-depth investigation and search for possible mechanistic explanations.
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Introduction
During spring-summer 2009, several observational studies from
Canada reported that prior receipt of the 2008–09 trivalent
inactivated influenza vaccine (TIV) was associated with increased
risk of medically-attended, laboratory-confirmed A(H1N1)pdm09
illness, with estimated risk or odds ratios of 1.4–2.5 compared to
those unvaccinated [1]. This increased risk was not apparent
among vaccinated people when comparing hospitalized to
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community cases [1], and observational studies in other settings
showed contradictory results, including increased [2–5], null [6–9]
or protective [10,11] effects from vaccination. Hypotheses to
explain findings from Canada initially focused on methodologic
(observational designs) or product-specific (domestically-manufac-
tured vaccine) considerations. However, a randomized-controlled
trial (RCT) in Hong Kong spanning November 2008 to October
2009 also showed significantly increased relative risk (2.58) among
children who had received a different manufacturer’s 2008–09
TIV product (Vaxigrip, Sanofi Pasteur, Lyon, France) [12,13].
Previous ferret studies have also shown mixed results although
none have demonstrated 2008–09 TIV to have been protective
against A(H1N1)pdm09[14–19]. Two small ferret studies reported
no TIV effect on virus replication in nasal or lung specimens
[14,15] but, where clinical outcomes have been assessed, several
studies have shown consistent albeit non-significant trend toward
greater weight loss and worsening of severity indicators in
vaccinated ferrets [16–19]. All of these ferret studies to date,
however, have suffered from small sample size, typically compar-
ing #5 animals per group in total.
Mechanistic hypotheses to explain increased A(H1N1)pdm09
risk among prior TIV recipients have included both direct and
indirect vaccine effects [1]. The direct effect hypothesis postulates
that seasonal vaccine may directly influence host resistance to
pandemic virus infection and/or replication whereas the indirect
hypothesis proposes that seasonal vaccine may block the more
robust, complex and cross-protective immunity otherwise afforded
by seasonal virus infection thereby indirectly increasing the risk of
pandemic illness. Here we report on a randomized, blinded,
placebo-controlled ferret study to test whether the commercially-
available TIV predominantly used in Canada in 2008–09 may
have directly influenced A(H1N1)pdm09 disease risk.
Materials and Methods
Ethics Statement
Animal procedures were approved by the Institutional Animal
Care Committee of Laval University according to the guidelines of
the Canadian Council on Animal Care (protocol 2011055).
Overview
Experimental procedures were conducted at the Laval Univer-
sity animal care facility in Que´bec between April 27 and July 4,
2011 (Figure 1). Animals were housed two per cage in the same
room and permitted food and water ad libitum.
The primary outcome of this study was weight loss. Sample size
was assigned to test differences in proportionate weight loss from
baseline following infection with pandemic H1N1 virus. Based on
80% power and 2-sided alpha of 0.05 to detect mean difference in
weight loss relative to baseline of 5% in the placebo group and
10% in the vaccine group, and given standard deviation (SD) of 4–
5%, 12–17 ferrets per group would be required. We used 16 ferrets
per group.
Intervention
Thirty-two male ferrets were randomly assigned to receive
0.5 mL intra-muscular injection of either 2008–09 TIV (‘‘vac-
cine’’) or PBS (‘‘placebo’’) on days 0 and 28. Study personnel and
investigators remained blinded to vaccine/placebo assignment
throughout experimental procedures and assays. GlaxoSmithKline
(GSK Fluviral; manufactured in Laval, Que´bec, Canada) and
Sanofi Pasteur (Vaxigrip; manufactured in Lyon, France) supplied
approximately 75% and 25%, respectively, of the seasonal split
TIV distributed in Canada during the 2008–09 season. In this
experiment we therefore used the dominant Canadian manufac-
tured, commercially-available, non-adjuvanted GSK sodium
deoxycholate split-antigen Fluviral containing the three WHO-
recommended vaccine components: A/Brisbane/59/
2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Flor-
ida/4/2006(Yamagata)-like [20]. Manufacturers substituted the
egg-adapted reassortant strains A/Brisbane/59/2007(H1N1)
IVR-148 (hereafter ‘‘IVR-148’’) and A/Uruguay/716/
2007(H3N2) NYMC X-175C (hereafter ‘‘X-175C’’) as considered
antigenically-equivalent vaccine components.
The potency of all three vaccine strains of the post-expiry but
cold-chain maintained 2008–09 Fluviral lot that was used was
confirmed by single radial immuno-diffusion (SRID) testing by the
Center for Biologics Evaluation and Research, United States (US)
Food and Drug Administration (FDA) [21]. US specifications
require $27 mg/mL hemagglutinin (HA) for each antigen (dose
0.5 mL) based on the mean of three tests, with additional
requirements around the standard deviation (SD). As last assessed
in February 2012, for each antigen, mean HA content for the TIV
lot used remained $30 mg/mL with SDs within required
specifications.
Figure 1. Study protocol. Randomized blinded placebo-controlled experiment of Canadian manufactured, commercially-available 2008–09
trivalent inactivated influenza vaccine (TIV: Fluviral) on A(H1N1)pdm09 disease risk in ferrets.
doi:10.1371/journal.pone.0086555.g001
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Challenge and Sacrifice
On day 49, animals were lightly anesthetized and challenged
(Ch0) intra-nasally with 250 mL (4.5logTCID50/mL) [22,23] of a
Que´bec A(H1N1)pdm09 isolate (A/Que´bec/144147/2009; prop-
agated thrice in vitro in Madin-Darby canine kidney (MDCK)
cells; GenBank: FN434457–FN434464) (Table S1), administered
half-volume per nostril. Four randomly-selected ferrets per group
were sacrificed on day 54 (i.e. 5 days post-challenge: Ch+5) and
the remainder sacrificed on day 63 (i.e. 14 days post-challenge:
Ch+14).
Antibody Response
Pre-shipment sera collected between March 14 and 24, 2011
and serum samples from anesthetized animals collected on days 0
(May 2, 2011), 28, 49 (Ch0), 54 (Ch+5) and 63 (Ch+14) were
assessed for antibody to TIV components and A(H1N1)pdm09 by
haemagglutination inhibition (HI), microneutralization (MN),
nucleoprotein (NP)-based ELISA and HA1-based protein micro-
array assays.
Hemagglutination inhibition and microneutralization –
antigens and analyses. Reference viruses used in the HI and
MN assays were obtained from Canada’s Influenza Reference
Laboratory, the National Microbiology Laboratory (NML),
Winnipeg, and passaged in MDCK cells two to three times
(Table S1). MDCK-passaged viruses were tested by both HI and
MN against reference ferret anti-serum provided by the NML,
confirming antigenic integrity was maintained relative to the
WHO-recommended reference viruses. Viral hemagglutinin (HA)
and neuraminidase (NA) were also sequenced to assess amino acid
(AA) identity relative to WHO reference viruses and the actual
vaccine components selected by the manufacturer (Table S1 and
Table S2). Compared to respective vaccine strains, passaged
assay viruses showed complete HA and NA identity for seasonal
H1N1 and $98% for H3N2. Compared to challenge virus,
passaged A(H1N1)pdm09 assay virus also showed $98% HA and
NA identity. Percent identity was reduced as expected when
comparing seasonal to pandemic H1 strains (72–73% in the HA1
protein).
HI and MN assays were conducted in duplicate according to
established protocols [24] as detailed below and the individual
result assigned as the geometric mean titer (GMT) of duplicate
values. Summary HI and MN serologic statistics were compared
including the number meeting threshold titers of 10 and of 40.
Changes in titers from baseline (day 0) to days 28, 49 (Ch0), and
54 (Ch+5) or 63 (Ch+14) were assessed through sero-conversion,
group GMTs with 95% confidence intervals (CI) and group GMT
ratios (GMTR).
Haemagglutination inhibition methods. In preparation
for the HI assay, sera were treated with receptor destroying
enzyme (Accurate Chemical & Scientific, NY) to remove non-
specific inhibitors of agglutination, and further hemadsorbed with
50% turkey erythrocytes (Lampire Biologic Laboratories, Penn-
sylvania). Sera were serially diluted beginning at 1:10 with
phosphate buffered saline and 25 mL of each serum dilution was
reacted with 25 mL of antigen (infected MDCK cell lysate
supernatant) containing 4 HA units of virus for 30 minutes. To
each mixture 50 mL of 0.5% turkey erythrocytes were added, and
after mixing, the preparations were incubated for 30 minutes.
Results were recorded by photography. The HI titer was
designated as the inverse of the highest dilution at which
detectable HI activity was still present. Influenza B virus was
used in the HI assay in its ether-treated, inactivated form. Briefly,
the clarified influenza B virus cell lysates were each mixed by
agitation with an equal volume of diethyl ether. The mixture was
kept at 4uC for 15 minutes to allow for the phases to separate. The
top ether layer was aspirated and nitrogen gas bubbled through
the virus preparation to remove residual ether, and the prepara-
tion was then used in the HI assay.
Microneutralization methods. For MN assay, 50% tissue
culture infectious dose (TCID50) viral titers were determined on
MDCK cells. The sera were treated with receptor destroying
enzyme (Accurate Chemical & Scientific, NY) and serially diluted
in serum-free medium (MegaVir, HyClone, Utah) beginning at
1:10. To each 50 mL dilution, 100 infectious units of virus were
added. The plates were incubated for 2 hours at 37uC to allow for
virus antibody interaction. The contents of each well were then
transferred onto microtiter plates with confluent monolayers of
MDCK cells. After 3 hours of further incubation at 37uC, the
medium in each well was removed and replaced with fresh
MegaVir medium containing 2 mg/mL L-1-tosylamido-2-pheny-
lethyl chloromethyl ketone (TPCK)-treated trypsin. The plates
were further incubated at 37uC and monitored for cytopathic
effects on days 3 and 5. The MN titer was defined as the inverse of
the serum dilution immediately preceding the wells with
cytopathic effects.
ELISA and HA1-based protein microarray
methods. Competitive ELISA was conducted on sera using a
commercially-available NP-based influenza A antibody test kit
from IDEXX Laboratories, Inc. (Switzerland) [25]. Competitive
ELISA antibody values were calculated as sample optical density
(OD) divided by negative control OD with ratios ,0.60
considered positive and mean values with 95%CI displayed;
smaller ELISA ratios denote higher antibody levels.
An HA1-based protein microarray serological assay was
conducted for study and non-study antigens listed in Table S3,
performed as previously described [26] with adaptation for
detection of ferret antibodies. Serum samples were tested in a
single 1:10 dilution in Blotto containing 0.1% Surfact Ampt (both
Thermo Fisher Scientific Inc., Rockford, USA). All incubation
steps were one hour at 37uC. Recombinant HA1 proteins were
spotted in duplicate and incubated with 70 mL Blotto followed by
70 mL of diluted ferret serum and then two-step conjugation by
incubation with 70 mL mouse anti-mustelid IgG (Antibodies-
online, Aachen, Germany) followed by 70 mL Dylight 649-
conjugated goat anti-mouse IgG (Jackson Immunoresearch,
Baltimore pike, USA) both in Blotto containing 0.1% Surfact
Ampt. After washing and drying, the slides were scanned using a
Powerscanner (Tecan, Ma¨nnedorf, Switzerland) and signals
quantified using a Scanarray scanner (Perkin Elmer, Waltham,
USA). Individual spot signals were valued with correction by
subtraction for per spot background fluorescence, truncated at
zero where signal was below background. Final individual per
ferret values were assigned as the average of duplicates, log10-
transformed after imputing a value of 0.1 for any zero values and
compared for each antigen by study group and day.
Clinical Monitoring
Activity, rectal temperature, appetite and weight were recorded
daily from days 42 through 46 and then from challenge (day 49;
Ch0) until sacrifice. Baseline reference weight per ferret was
computed as the average of day 42 to 46 and Ch0 weights. Activity
was scored 1–5: one being the most alert and playful; two, alert but
playful only if induced; three, alert but not playful (stays in hiding
place); four, neither alert nor playful and five was the humane
endpoint. Appetite was scored as usual, diminished or no appetite.
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Nasal Wash and Lung Virus Quantification
A(H1N1)pdm09 virus titers were assessed in nasal wash pre-
challenge day 46 and daily post-challenge (Ch+1) until sacrifice
and in whole right lung homogenates at each scheduled sacrifice.
Virus titers were determined by standard plaque assays using
St6GalI-expressing MDCK cells [27,28], expressed as log10-
transformed plaque-forming units (pfu) per mL.
Lung Histopathology and Immuno-histochemistry
Paraffin tissue sections were prepared from whole left lung of
ferrets for histo-pathology assessment at each scheduled sacrifice.
Inflammation was graded on six indicators (bronchial/endobron-
chial, peribronchial, perivascular, interstitial, pleural and intra-
alveolar), each scored as: 0 (normal), 1 (mild), 2 (moderate) or 3
(marked) for a maximum combined score of 18 [28]. Vascular
congestion and pulmonary edema were similarly scored.
Lung immuno-histochemistry was undertaken to identify cells
with virus antigen. Paraffin tissue sections were quenched for 10
minutes in aqueous 3% H2O2 then pre-treated with proteinase K
for 15 minutes. A 1:10,000 dilution of mouse monoclonal antibody
to influenza A nucleoprotein (F26NP9; in-house) was applied for
one hour. Sections were visualized using horseradish peroxidase-
labelled polymer, EnvisionH+system (anti-mouse) (Dako, USA),
reacted with the chromogen, diaminobenzidine and counter-
stained with Gill’s hematoxylin.
Lung Cytokine Response
Change in lung cytokine mRNA gene expression was assessed
by relative quantitative PCR (qPCR) with RNA extracted from
140 mL of right lung homogenate using the QIAamp viral RNA
mini-kit. Reverse transcription was performed using the High
Capacity RNA-to-cDNA Kit (Applied Biosystems) on 0.5 mg of the
total RNA following manufacturer’s protocol. qPCR was per-
formed using the TaqManH Gene Expression Master Mix (ABI)
with primers designed to target published cytokine sequences [29–
31] from Mustela putorius furo mRNA sequences at a final
concentration of 0.25 mM. Assays were run on the StepOne Plus
(ABI) with the following conditions: 50uC–2 minutes; 95uC–10
minutes; followed by 40 cycles of 95uC–15 seconds; and 60uC–1
minute. Fold-change was calculated using the delta-delta Ct
method [32] with uninfected ferrets as reference and GAPDH as
endogenous control.
Statistical Methods
Chi-square or Fisher’s exact test were used to compare
categorical variables and t-test or Wilcoxon methods for contin-
uous variables. Weight, nasal virus titers, and HA1 protein
microarray values were analysed via contrasts in a mixed-effects
linear model (group, visit and their interaction, with repeated
measurements on each animal). For protein microarray values,
analyses were repeated after excluding statistical outliers without
substantively affecting main conclusions. Inflammatory scores by
individual ferret are presented and combined inflammatory scores
and cytokine values at Ch+5 versus Ch+14 were compared via
contrasts in a two-way ANOVA model (group, scheduled sacrifice
day and their interaction). Observed p,0.05 are described as
significant; no attempt is made to correct for multiple inference.
Results
Antibody Response
Individual HI, MN and ELISA assay results are displayed
concurrently for pre-shipment, day 0, 28, 49 and 54/63 time
points, for the four vaccinated and four placebo animals sacrificed
at Ch+5 in Table S4, and for the 12 animals per group sacrificed
at day 63 in Table S5 for vaccinated animals and Table S6 for
placebo animals. Summary ELISA results are shown in Table 1
and summary microarray results for study antigens in Figure 2
with study and non-study antigen cross-reactive responses shown
in Figure S1. Summary HI and MN statistics are shown in
Table S7 and Table S8, respectively.
All animals were confirmed by NP-based ELISA to be influenza
A naı¨ve at pre-shipment and day 0. By day 49 there was significant
ELISA antibody rise following immunization in the vaccine group,
with further antibody rise evident by day 54 (Ch+5) after
A(H1N1)pdm09 challenge in vaccinated animals but not until
day 63 (Ch+14) in placebo ferrets (Table 1, Table S4, Table
S5, Table S6). Ultimately, total influenza A ELISA antibody was
significantly higher among vaccine compared to placebo animals
at both scheduled sacrifices (Table 1).
Protein microarray results were consistent with ELISA but in
addition showed vaccine-induced HA1 antibody to the seasonal
H1 antigen, for which values were significantly higher in
vaccinated animals relative to pre-immunization and compared
to placebo from day 28, most pronounced from day 49 after the
first TIV dose (i.e. three weeks after two-dose vaccine series
completion) (Figure 2). There was significant rise in antibody
relative to pre-immunization for the H3N2 vaccine component at
day 49, but only relative to the placebo group at day 63 (i.e. five
weeks after vaccine series completion). Slight but significant
decrease in A(H1N1)pdm09 antibody was evident at day 28 post-
immunization compared to baseline but not thereafter or relative
to placebo, calling into question its clinical relevance. Significant
rise in antibody to A(H1N1)pdm09 relative to pre-immunization
was evident at day 63 in both the vaccine and placebo groups. Of
interest, infection with A(H1N1)pdm09 induced antibody by day
63 not only to itself but also to closely related 1918 H1 antigen in
both study groups (significantly higher for the latter in the
vaccinated) (Figure S1). Furthermore, at day 63 among
vaccinated but not among placebo animals, A(H1N1)pdm09
challenge induced significantly greater cross-reactivity to non-
study (1977, 1999) H1 variants to which the animals had never
been exposed, evident relative to pre-immunization, to the placebo
group and to pre-challenge at day 49 (Figure S1). Increase
following A(H1N1)pdm09 challenge among the vaccinated was
evident at day 63 for other non-H1, non-vaccine antigens (H2,
H3) relative to pre-immunization but not relative to placebo.
All animals were also shown by HI and MN assays to be
influenza naı¨ve at pre-shipment (Table S4, Table S5, Table
S6). More variability in HI than MN antibody titers was evident
thereafter. Overall, however, the significant rise in vaccine-
induced antibody shown by ELISA and HA1 protein microarray
by day 49 was not evident by HI or MN assays except among a
few of the vaccinated ferrets (Table S4, Table S5). Conversely,
ferrets in both groups showed substantial neutralizing antibody to
A(H1N1)pdm09 at day 63 (Table S5, Table S6) with very high
GMTs and GMTRs relative to baseline, slightly (but non-
significantly) higher in the placebo compared to the vaccine
group by both HI and MN (Table S7, Table S8).
Clinical Findings
Average baseline weight was comparable between the vaccine
(0.96 Kg) and placebo (0.97 Kg) groups (p = 0.87). Beginning at
Ch+2, more vaccinated animals showed diminished or no appetite
compared to placebo recipients (7/16 versus 3/16; p = 0.25) with
the greatest between-group difference at Ch+5 (12/16 versus 6/
16; p = 0.07), that resolved by Ch+10 (1/12 vs. 0/12; p = 1.0). The
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greatest between-group difference for no appetite was at Ch+6 (7/
12 vs. 1/12; p = 0.03).
Weight loss from baseline was greater in the vaccine than
placebo group, evident beginning at Ch+2 and marginally
significant across the full study period (% weight loss p = 0.048;
absolute loss p = 0.06) (Figure 3A). The greatest between-group
difference in percentage weight loss from baseline was at Ch+5
(7.4% vs. 5.2%; p = 0.01) (Figure 3A) on which day 4/16 (25%)
vaccinated versus 1/16 (6%) placebo animals had lost 10% or
more of their body weight compared to baseline (p = 0.3) (Table
S4, Table S5, Table S6). Consistent with random selection, the
same pattern was evident regardless of sacrifice day, with mean
percentage weight loss from baseline at Ch+5 of 6.9% for the
vaccine group and 4.6% for the placebo group among animals
selected for sacrifice at Ch+5 and 7.6% and 5.3%, respectively,
among animals sacrificed instead at Ch+14. Animals had
comparable scores of one for alertness/playfulness at all time
points except from Ch+2–8 for which activity levels were
marginally worse (scored as two) in all animals in both groups.
Temperature patterns did not differ between vaccine and placebo
groups with a peak in mean/median temperatures at Ch+2 of
40.0uC and 40.1uC, respectively.
Nasal Wash and Lung Virus Quantification
Nasal A(H1N1)pdm09 titers did not differ significantly between
groups over time (p = 0.37). Nasal virus titers rose more steeply
between Ch+1–2 in the vaccine versus placebo group (mean
difference in log-titres 1.14 versus 0.88 pfu/mL; p = 0.25) and then
fell more steeply at Ch+2–3 (mean difference in log-titres 0.80
versus 0.46 pfu/mL; p = 0.01) (Figure 3B).
Lung A(H1N1)pdm09 titers at Ch+5 were significantly higher in
the vaccine versus placebo group (log-mean 4.96 versus 4.23 pfu/
mL; p = 0.01) (Figure 3C). Neither group had detectable virus in
the lung at Ch+14.
Lung Histopathology
At Ch+5, animals sacrificed from the vaccine group had higher
combined mean/median lung inflammatory scores than placebo
animals (5.8/5.5 versus 2.1/2.0), a difference that did not reach
statistical significance (p = 0.051) (Table S9). Two of four
Figure 2. HA1 microarray serological values by study antigens, group and day. Box plots display median (dash) and mean (dot) of log10-
transformed HA1 protein microarray signal values. The box extends to the 25th/75th percentiles and whiskers extend to minimum/maximum values.
H1-07 indicates A/Brisbane/59/2007 (H1N1)-like; H3-07 indicates A/Brisbane/10/2007 (H3N2)-like; H1-09 indicates A/California/7/2009 (H1N1)pdm09-
like (Table S3; grey-shaded). Sample size as follows: Pre-immunization Vaccine = 15, Placebo = 16 (3 ferrets each per group pre-shipment serum was
substituted owing to insufficient day 0 available); Day 28 Vaccine = 14, Placebo = 15; Day 49 Vaccine = 12, Placebo = 11; Day 54 Vaccine = 2,
Placebo = 4; Day 63 Vaccine = 9, Placebo = 8. **indicates statistical significance at p,0.01 and *indicates statistical significance at p,0.05 in
comparing vaccine to placebo group at the designated time point. DD indicates statistical significance at p,0.01 and D indicates statistical
significance at p,0.05 in comparing values within study groups at days 28, 49, 54 and 63 relative to pre-immunization, colour coded by vaccine (red)
or placebo (blue). %% indicates statistical significance at p,0.01 and % indicates statistical significance at p,0.05 in comparing day 63 to day 49
within groups, colour coded per above by study group.
doi:10.1371/journal.pone.0086555.g002
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vaccinated animals showed a combined lung inflammatory score
of $10 at Ch+5 compared to none of the four placebo animals
(maximum score = 4) (Table S9). Salient histologic features are
shown in Figure 4 for animals of both groups with the highest
and lowest combined Ch+5 inflammatory scores, illustrating the
severe bronchopneumonia that was evident in half of the
vaccinated but none of the placebo animals. The increased
micrometric scale in panel D reflects that the pathologic changes
are marked and diffuse, best rendered at low magnification,
whereas the mild to moderate and more focal changes in panels A
to C necessitate photomicrographs at higher magnification.
Compared to Ch+5, combined mean lung inflammatory score
was significantly lower in the vaccine group among animals
sacrificed at Ch+14 (5.8 vs. 1.8; p = 0.01) whereas this showed little
change over time in the placebo group (2.1 vs. 2.4; p = 0.84) with
significant interaction between scheduled sacrifice day and group
(p = 0.048). Combined mean/median lung inflammatory scores
were not significantly different between the vaccine versus placebo
group at Ch+14 (1.8/1.2 versus 2.4/1.5).
In both the vaccine and placebo groups at Ch+5, influenza
antigen was detected by immuno-staining in bronchial and
bronchiolar epithelium. Within alveolar walls, most of the positive
cells were identified as pneumocytes using double immuno-
labelling [not shown]. Occasional cells had the morphology of
macrophages. No viral antigen was detected in animals at Ch+14.
Lung Cytokines
IFN gamma was below the limits of detection in both groups at
both scheduled sacrifices. Other lung cytokines were consistently
but non-significantly higher in the vaccine versus placebo group at
Ch+5. All cytokine values were lower in both groups at Ch+14,
consistently but non-significantly lower in the vaccine animals.
The Ch+5 versus Ch+14 difference was statistically significant for
all vaccine group cytokines (all p#0.02) except IFN alpha
(p.0.05) whereas differences were not significant in the placebo
group, except for IL17 (p = 0.046). Overall, the interaction
between scheduled sacrifice day and study group was not
significant for any cytokine (Figures 5A and 5B).
Discussion
During spring-summer 2009, several observational studies from
Canada reported that prior recipients of 2008–09 TIV experi-
enced approximately two-fold increased risk of medically-attend-
ed, laboratory-confirmed A(H1N1)pdm09 illness [1]. Recognizing
that all observational designs are susceptible to methodological
bias, gold standard RCT analysis would typically be considered
essential in clarifying such unexpected findings. In Hong Kong, an
RCT of the 2008–09 TIV (Vaxigrip) already underway had shown
similar association among vaccinated children with significant
relative risk of 2.58 (increased to 2.74 with adjustment for seasonal
infection) [12,13]; however, during follow-up RCT using 2009–10
Vaxigrip and spanning August 2009 to December 2010, the same
investigators instead reported significant protective effects [33].
Both RCTs lacked sufficient power for analysis based on
virologically-confirmed infection so that conclusions were drawn
instead from less reliable serologically-defined outcomes [12,33].
Further RCT test of the association in humans has now become
practically impossible given that, since fall 2010, all seasonal TIV
routinely contains protective, homologous A(H1N1)pdm09 anti-
gen [20]. We therefore undertook RCT evaluation of the possible
direct effects of prior heterologous TIV receipt on A(H1N1)pdm09
disease risk in ferrets as the ideal alternate model of human
influenza infection [34].
Although none of the animals became moribund or so severely
ill as to require euthanasia, ferrets immunized with two doses of
2008–09 TIV did show significantly worse clinical, virologic and
pathological features following pandemic H1N1 infection com-
pared to placebo recipients. As originally powered to show,
vaccinated animals experienced significantly greater weight loss
relative to baseline following infection, maximally different from
placebo at Ch+5. Nasal wash titers did not differ, but vaccinated
animals showed significantly higher lung virus titers. Consistent
with lung virus findings, lung inflammation was also increased
more than 2.5-fold in vaccinated compared to placebo animals at
Ch+5 although with fewer animals sacrificed on that day the
difference fell just short of statistical significance. Inflammatory
indicators were, however, significantly higher at Ch+5 compared
to Ch+14 in the vaccinated animals and showed no change across
Table 1. Influenza A antibody results by study day and group based on ELISA assay.
Number ELISA antibody positive/Number of sera
testeda
Mean ELISA antibody result (95% confidence
interval)b
Time point (N randomized
per group) Vaccine Placebo Vaccine Placebo
Pre-Shipment (16) 0/16 0/16 1.18 (1.09–1.27) 1.18 (1.08–1.28)
Day 0 (16) 0/16c 0/16c 1.03 (0.98–1.08) 1.02 (0.96–1.09)
Day 28 (16) ND ND ND ND
Day 49/Ch0 (16) 10/14 0/13 0.51 (0.35–0.66) 1.03 (0.99–1.06)
Day 54/Ch+5 (4) 4/4 0/4 0.21 (0.09–0.33) 1.03 (0.89–1.15)
Day 63/Ch+14 (12) 10/10 9d/11 0.17 (0.09–0.25) 0.46 (0.39–0.53)
Competitive Nucleoprotein-based IDEXX ELISA (Influenza A antibody). Ratios ,0.60 classified as positive; ratios $0.60 classified as negative.
ND = Not done; IDEXX Inc. = Commercial ELISA assay (note the lower the ratio, the greater the antibody detected); Ch = challenge.
aWhere numbers tested differ from the number randomized per group in parentheses at the specified time point it is because insufficient sera remained for testing of all
animals.
bNumber of sera tested by group shown in adjacent columns.
cOne day 0 serum in each group was insufficient for ELISA testing and substituted with pre-shipment values for these ferrets. Excluding these ferrets (leaving n = 15 per
group) gives ELISA ratios of 1.04 (0.99–1.09) and 1.05 (1.01–1.09) for vaccine and placebo groups, respectively.
dTwo sera belonging to placebo group close to serologic threshold for positivity with ratios of 0.61.
doi:10.1371/journal.pone.0086555.t001
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that period in placebo recipients. Lung cytokines showed a similar
pattern. Although illness activity levels appeared similar between
groups based on categories of induced playfulness, these may have
been of insufficient resolution to reflect clinical differences in lung
disease, manifest otherwise through significant loss of appetite and
weight.
By day 14 post-challenge animals in both groups had recovered.
In human studies, a doubling of the risk of medically-attended
pandemic H1N1 illness was observed among 2008–09 TIV
recipients, but an increase in the risk of hospitalization was not
shown [1]. This was broadly interpreted to suggest increased risk
of acquiring infection per se whereas here we report increased disease
severity among influenza-naı¨ve, systematically-infected ferrets. As
such, our findings in ferrets may not replicate the experience in
humans. It is worth noting, however, that the source population in
the human observational studies was patients seeking medical care
[1]. Although illness severity among outpatient visits was not
specifically compared between vaccinated and unvaccinated
participants, subjects had experienced influenza-like illness severe
enough to prompt medical consultation within one week of illness
onset, and that outcome was significantly increased among the
vaccinated. In that regard, the pattern of acute worsening of
A(H1N1)pdm09 illness during the first week of infection in
vaccinated ferrets, followed by subsequent recovery by day 14, is
consistent with increased outpatient but not hospitalization risk
observed in vaccinated humans. As such, this ferret RCT suggests
that earlier findings from observational studies in humans cannot
be dismissed on the basis of methodological bias alone and that
direct mechanistic explanations should be sought. Whether these
findings may be product-specific or may also apply to other TIV
products has yet to be separately assessed in follow-up studies.
To date, hypotheses about biological mechanisms to explain
increased A(H1N1)pdm09 risk among prior TIV recipients have
included both direct and indirect vaccine effects [1]. Indirect
mechanisms include the infection block hypothesis whereby
effective seasonal vaccine may prevent the more robust and
complex cross-protective immunity against heterologous viruses
afforded by seasonal infection, such as through cell-mediated
responses to conserved internal virus components [1,35,36]. Other
epidemiological investigators have favoured this hypothesis, or
related variations (such as temporary immunity hypothesis)
[33,37], but in Appendix G of our original publication [1] we
demonstrated these indirect hypotheses to be insufficient and
implausible to fully explain a doubling of risk, requiring as they do
unreasonably high estimates of infection attack rates, infection-
induced cross-protection, and TIV effectiveness [1,13]. To test
whether increased risk in vaccinees may have occurred without
invoking infection block mechanisms we specifically designed the
current ferret experiment without the intermediary of heterolo-
gous seasonal influenza infection. As such, we cannot rule out an
additive role for indirect vaccine effects mediated through
infection block mechanisms, but show that direct vaccine effects
are likely to have at least contributed to our previous findings.
Possible direct vaccine effects include antibody-dependent
enhancement (ADE) whereby virus uptake by cells is enhanced
in the presence of low-level, cross-reactive, non-neutralizing
antibodies, best described for dengue [1,38,39]. A possible role
for cross-reactive antibodies in explaining severe A(H1N1)pdm09
manifestations in otherwise healthy adults, and in archived lung
sections from fatal adult cases during the 1957 H2 pandemic has
previously been suggested [40]. Another recent study has reported
an association between higher ratios of cross-reactive ELISA
versus neutralizing antibody titers early during A(H1N1)pdm09
infection and more severe illness [41]. Enhanced respiratory
Figure 3. Clinical outcomes including weight loss, nasal wash
and lung virus titers by study group and day. Clinical outcomes
are displayed including: (A) Mean percentage weight relative to
baseline by study group and day, with standard errors. (B) Nasal wash
virus titers by study group and day. (C) Lung homogenate virus titers at
day 5 post-challenge. Box plots (B and C) display mean (dot) and
median (line) virus titres as log pfu/mL. Per usual, the box extends to
the 25th/75th percentiles and whiskers extend to minimum/maximum
values. Ch refers to challenge day and Ch+1, Ch+2 etc indicate day post-
challenge (i.e. day one post-challenge, day two post-challenge etc).
Ch+5 indicates day five post-challenge on which four animals per group
were randomly selected for sacrifice. Statistically significant between-
group differences are as specified.
doi:10.1371/journal.pone.0086555.g003
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disease in vaccinated swine has also been reported following
challenge with A(H1N1)pdm09 or other heterologous, homo-
subtypic H1 viruses that do not share cross-reactive neutralizing
antibodies [42–45]. As in our ferret experiment, clinical worsening
in vaccinated swine was evident at two to five days post-challenge
[43,44] and was correlated with elevated pro-inflammatory
cytokine responses in the lung [44]. Unlike the current ferret or
prior human studies, however, these swine studies used adjuvanted
whole virion vaccine that was additionally heterosubtypic for the
neuraminidase surface protein (i.e. N2 versus N1), the relevance of
which is uncertain. ADE is classically associated with enhanced
virus uptake in macrophages or other Fc-receptor-bearing cells,
demonstrated in vitro for influenza [46–49] and more recently
also specifically for A(H1N1)pdm09 in the presence of heterolo-
gous human anti-sera [50]. In our vaccinated ferrets, higher lung
virus titers were observed, but immuno-histochemistry could not
distinguish affected cells of the lung in vaccine versus placebo
animals, and macrophages were not predominant in either group.
More recently in swine, however, heterologous antibody has been
shown to enhance A(H1N1)pdm09 infection of other mammalian
(MDCK) cells, described in the context of fusion-enhancing cross-
reactive anti-HA2 stalk antibodies and absent neutralizing
antibodies targeting the HA1 globular head [51,52].
Our experiment was unable to further elucidate these putative
immunologic mechanisms. We identified significant vaccine-
induced influenza A antibody rise by ELISA and confirmed this
to include anti-HA1 antibody response to the seasonal H1N1 TIV
component. There was also rapid and significant increase in
influenza A ELISA antibody following A(H1N1)pdm09 challenge
among vaccinated but not placebo ferrets sacrificed at Ch+5 but
HA1-based and neutralizing antibodies to A(H1N1)pdm09 were
not evident until Ch+14 in either group. Lower neutralizing
antibody to A(H1N1)pdm09 even at Ch+14 among vaccinated
versus placebo ferrets, although not statistically significant, is
consistent with human immunogenicity trials showing blunting of
pandemic H1N1 vaccine-induced responses in association with
prior seasonal vaccine receipt [53–56]. Conversely, pandemic
H1N1 immunization has been observed to boost pre-existing
heterosubtypic antibody which may also be consistent with our
Ch+14 findings for the H3N2 TIV component and the broad
boosting of cross-reactive antibodies to other antigenically-distant
H1 variants observed by protein microarray in vaccinated but not
placebo animals [57]. Although protein microarray did not show
cross-reactive A(H1N1)pdm09 antibody prior to Ch+14, it was not
designed to detect the sort of anti-HA2 stalk antibodies highlighted
above in association with severe disease in vaccinated swine [51].
Ultimately, therefore, we are unable to discern whether the rise in
Ch+5 ELISA antibody in vaccinated animals suggests early cross-
reactive, non-neutralizing antibody to A(H1N1)pdm09 or further
antibody increase to TIV antigens 4 weeks after their second dose
(or both) although microarray indicates the latter certainly
contributed.
T-cell hypo-responsiveness may be an alternate explanation
compatible with a hypothesis of direct vaccine effect. This
phenomenon has been reported in same-season influenza vaccine
booster-dose studies [58] with parallels also in the allergy literature
suggesting peptide-induced T-cell hypo-responsiveness beginning
at 2–8 weeks and lasting up to 40 weeks [59]. However, while
Figure 4. Ferret lung histology at day 5 post-challenge (Ch+5). Salient lung histologic features (hematoxylin eosin stain micrometric scale in
lower left of each panel) including vaccine and placebo ferrets with highest and lowest combined Ch+5 inflammatory scores within their group: (A)
Ferret #81 (placebo; inflammatory score 0.5) indicating very mild/minimal peri-bronchial inflammation; (B) Ferret #63 (vaccinated; inflammatory
score 0.5) indicating very mild/minimal peri-vascular inflammation; (C) Ferret #58 (placebo; inflammatory score 4.0) indicating moderate bronchial
and mild peri-bronchial/peri-vascular inflammation; (D) Ferret #69 (vaccinated; inflammatory score 11.5) indicating severe bronchopneumonia. The
increased micrometric scale in panel D reflects that the pathologic changes are marked and diffuse, best rendered at low magnification, whereas the
mild to moderate and more focal changes in panels A to C necessitate photomicrographs at higher magnification. Corresponding histopathology
scores are shown in Table S9.
doi:10.1371/journal.pone.0086555.g004
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interferon-gamma was below detectable limits in both groups, lung
cytokines in vaccinated ferrets were otherwise consistently (but
non-significantly) higher compared to placebo animals at Ch+5,
notably including the Th2 IL4 [60], pro-inflammatory IL17
[61,62] and regulatory IL10 [63] cytokines. IL17 has been
implicated as super-inducer of neutrophil infiltration and acute
lung immuno-pathology following influenza infection [62], with
counteractive dampening interactions by IL10 [63]. In an earlier
Canadian ferret experiment in which animals administered a
single dose of 2008–09 TIV also experienced worse
A(H1N1)pdm09 illness, IL6 in nasal wash was substantially raised
in the Fluviral group and IL10 significantly in the Flumist group,
with disease enhancement suggested in both vaccine groups
compared to controls [16]. We did not assess nasal wash cytokines
or Flumist and were not statistically powered to explore cytokine
differences, but lung IL6 and IL10 were also both non-significantly
raised at Ch+5 in our Fluviral versus placebo ferrets. All cytokine
values were then lower at Ch+14 in the absence of lung pathology.
However, none of the between-group cytokine differences at either
time point were statistically significant.
There are limitations to this study. Although ferrets are
considered the ideal animal model for human influenza infection,
there are anticipated differences in immunologic and clinical
aspects of immunization, infection and illness responses (timing,
dosing and intensity) across species. Overall patterns may be
compared but ferret studies do not support precise quantification
of actual risk in humans. The greater likelihood of more severe
disease based on several clinical indicators (weight loss, lung virus
titers) among vaccinated compared to unvaccinated ferrets may
not replicate the greater likelihood of medically-attended
Figure 5. Lung cytokine values at days 5 and 14 post-challenge with A(H1N1)pdm09 by study group. Per usual, box plots display mean
(dot) and median (dash) virus titers with box extending to the 25th/75th percentiles and whiskers extending to minimum/maximum values. Cytokine
values relative to control are displayed at (A) day 5 post challenge (Ch+5) on which four animals per group were randomly selected for sacrifice and
(B) day 14 post-challenge (Ch+14) on which the remaining 12 animals per group were sacrificed. Thus, at Ch+5, n = 4 (except IFN alpha for which n = 2
for placebo group) and at Ch+14, n = 12.
doi:10.1371/journal.pone.0086555.g005
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A(H1N1)pdm09 illness we previously reported in vaccinated
humans. In using influenza-naı¨ve, systematically infected ferrets
there are clear differences from the human experience with respect
to pre-conditions (influenza exposure history and immunologic
context), process (infection acquisition), and other relevant
parameters (vaccine immunogenicity, clinical outcomes and
monitoring). Clinical relevance of the differences we report
between vaccinated and placebo ferrets is ultimately best
interpreted in the context of our study objectives assigned in
follow up to the prior human observations we reported. The main
objective of the ferret study was to assess through randomized,
controlled design whether prior receipt of 2008–09 TIV may have
had direct, adverse effects on A(H1N1)pdm09 illness, specifically
powered related to weight loss. Although we cannot more precisely
elucidate the underlying mechanisms involved, the current ferret
study supports the hypothesis of direct vaccine effect. Taken
together with prior human and swine studies, these findings
represent a signal that warrant further investigation and better
understanding though they cannot be considered conclusive.
The most prominent concern in this ferret study may relate to
our failure to show neutralizing antibody response to vaccine, an
issue we therefore consider in detail. We observed some greater
albeit low-level variability in antibody titers by HI, a non-
functional assay, than by microneutralization or NP-based ELISA.
Intra- and inter-laboratory variability in antibody assay results is
well-recognized [64,65] and we thus interpret findings in the
context of combined HI, MN, and ELISA results, overall
indicating our animals were naı¨ve at pre-shipment and baseline.
Vaccine-induced HI and MN responses were not evident
thereafter but significant vaccine-induced antibody rise was shown
by both NP-based ELISA and HA1-based protein microarray
assays, the latter also shown only at high serum/low antibody
concentrations (i.e. testing dilution of 1:10). Although SRID testing
of the expired 2008–09 vaccine lot that we used still met standard
HA potency requirements for annual commercial vaccine
approval by the FDA [21], we cannot rule out other unrecognized
vaccine changes with time that may have been influential.
MDCK-passaged viruses used in our HI and MN assays were
antigenically equivalent to reference strains and amino acid
sequencing showed they were also identical in their HA and NA to
the 2008–09 H1N1 vaccine component. This argues against such
linear differences to explain the suboptimal neutralizing responses
we measured; however, we cannot rule out other conformational
changes to protein structure in the original vaccine comprised of
(sodium-deoxycholate) disrupted and inactivated virus. The H3N2
virus used in our assays was also antigenically equivalent to the
WHO-recommended reference virus with which it shared $98%
HA antigenic site amino acid identity. However, we did not
conduct antigenic testing in relation to the actual vaccine
component used by manufacturers and cannot rule out differences
between assay and vaccine viruses in the suboptimal vaccine
responses we measured (Table S1 and S2). Protein micro-array
also showed variable low-level response to the H3N2 component
among immunized ferrets at day 49, significantly greater than
placebo and compared to pre-immunization only at day 63 (i.e.
five weeks after the second vaccine dose). Whether the latter was
due to further antibody rise with time following immunization or
cross-reactive response following A(H1N1)pdm09 challenge is
unknown; however, similar effect was not observed relative to
placebo for other non-vaccine H3 subtype viruses included in the
microarray, suggesting H3N2 vaccine response.
Thresholds for defining antibody response are also anticipated
to vary across species and assays; these have not been cross-
correlated/2validated in ferrets for the various antigens and
assays we used. In fact, sero-protective thresholds have not yet
been established for ferrets by any assay. However, failure to
induce a robust HI or MN antibody response to inactivated
influenza vaccine in naı¨ve ferrets has long been recognized, after
single or several doses, in the absence of prior infection or adjuvant
for seasonal, novel or pandemic vaccines [66–73]. In order to
replicate more closely the observations in humans, we used a
commercially available, non-adjuvanted 2008–09 Fluviral lot that
had been administered in Canada. It is of note that in human
studies conducted with the same product in 2008–09 (pediatric)
[74], 2009–10 (elderly) [75] and in a mouse study conducted in
2010–11 [21], Fluviral also induced suboptimal HI and/or MN
responses to the same seasonal A/Brisbane/59/2007-like H1N1
vaccine antigen. For example, in the pediatric trial including
infants and toddlers 6–23 months of age similarly naı¨ve to
influenza as were our ferrets, the same schedule of two 0.5 mL
doses of a thimerosal-free version of the 2008–09 Fluviral induced
significantly lower H1N1 antibody responses than even half that
volume (0.25 mL) per dose of Vaxigrip [74]. Despite double the
HA content per dose, GMTs at four weeks post-immunization
with the 2008–09 Fluviral (39.8 [95%CI: 27.6–57.5]) were
significantly lower than with the 2008–09 Vaxigrip (100.2
[95%CI: 59.8–168.0]), lower still when Fluviral was administered
at the conventional 0.25 mL dose typically given to children this
age (30.0 [95%CI: 20.5–43.8]) [74]. A similar pattern, though less
pronounced, was also observed with the H3N2 component [74].
The reasons for diminished immunogenicity of the Canadian
vaccine are unknown although authors of the pediatric trial
proposed more complete clearance of intact virus among other
possible explanations.
In human observational studies, the 2008–09 TIV was still
shown to be protective overall against homologous seasonal
influenza [1]. Spring-summer 2009 observations of increased risk
of heterologous A(H1N1)09 illness were identified six or more
months after TIV receipt. In that regard, lower vaccine-induced
antibody titers in ferrets at our three-week post-immunization
A(H1N1)pdm09 challenge time point may better replicate end-of-
season antibody conditions when vaccinated humans were
exposed to A(H1N1)pdm09 virus. A prior ferret study to assess
the same 2008–09 Fluviral also suggested disease enhancement but
was able to induce homologous HI antibody response to the H1N1
component with mean antibody titre exceeding 100 within two
weeks of a single 0.5 mL vaccine dose [16], higher even than
induced in the pediatric study population cited above. Such
variability in serologic responses may reflect lot-to-lot or labora-
tory differences. Not knowing the precise mechanisms involved in
vaccine-associated enhanced respiratory disease, and unable to
exactly know or replicate the human immunologic context in
spring-summer 2009, we did not adjust the human vaccine
formulation, dose or schedule to force higher ferret vaccine
responses. Instead we focused on clinical parameters, recording
the observed effects according to standard immunization practice.
In general, ferret studies to date have suffered from small sample
size and insufficient power [14–19,76]. Our study was powered for
clinical (percentage weight loss) comparison and follow-up to 14
days post-challenge. Failure to reach statistical significance for
other consistent indicators should not prompt their dismissal but
should stimulate further investigation. It may be argued that lung
findings at Ch+5 were chance occurrences among few ferrets
poorly-representative of the full group experience. However,
animals in both groups were randomly and blindly selected for
Ch+5 sacrifice, the comparison of baseline and Ch+5 character-
istics showed no significant within-group differences according to
scheduled endpoint, and Ch+5 lung findings in vaccinated animals
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(higher virus titers and lung inflammation) were consistent with
overall clinical patterns (greater loss of appetite and weight).
Nevertheless, future experiments should be powered with more
animals to specifically examine these early acute clinical,
immunologic, and pathologic findings and explore their possible
mechanisms in greater detail.
We assessed only influenza-naı¨ve animals whereas most
humans, other than young children, will have prior potentially
cross-attenuating influenza infection history. The use of influenza-
naı¨ve animals in previous swine [42–45,51,52] and the current
ferret studies may be relevant to the increased severity highlighted
in vaccinated animals but to a lesser extent noted with the
association in people. Further experiments are needed to explore
nuances related to infection and/or immunization history which
additionally and variously complicate the human experience. In a
recent publication, disease enhancement was included among
possible hypotheses to explain greater 2009 pandemic H1
morbidity in the Americas compared to Australia, New Zealand
or Europe, with reference to findings in vaccinated swine
interpreted ecologically in the context of regional differences in
prior heterologous seasonal H1N1 virus circulation; given findings
in vaccinated ferrets and swine, however, regional differences in
prior heterologous seasonal H1N1 vaccine (i.e. TIV) coverage may
also be relevant to consider [77]. Of note, mechanisms such as
ADE, if explanatory, require a precise balance of low-level, cross-
reactive, non-neutralizing antibody to be manifest [1,38,39], a
particular but sliding immunologic scale that may not have been
captured in all animals or humans at the time of A(H1N1)pdm09
exposure. A spectrum of illness is anticipated with any infection
process and a greater likelihood of severity does not require that all
exposed individuals experience that outcome. However, this
additional immunologic complexity related to ADE, if involved,
may have contributed to the variability in clinical outcomes we
observed among vaccinated ferrets and to the variability in
reporting the association in humans. Our experiment assessed the
unique context of heterologous but homosubtypic pandemic
H1N1 challenge. It has been suggested that original antigenic
sin as an aspect of the cross-reactive, non-neutralizing antibody
required for ADE applies when antigenic differences of less than
33–42% exist across related but distinct prime-boost strains [38];
amino acid differences in the HA1 between the 2008–09 seasonal
and 2009 pandemic H1 antigens were within this range (72–73%
similarity; Table S2) with much closer homology (92%) across the
HA2 (18 amino acid differences across 222 residues). However,
without better understanding of the underlying mechanisms or
specific virologic interactions we cannot speculate whether the
same association could apply to other emerging heterologous or
hetero-subtypic variants; the antigenic distance and other criteria
required to define or forecast that likelihood remain unknown.
In summary, although these ferret findings cannot be consid-
ered conclusive in explaining earlier human observations from
Canada, they support the hypothesis that prior receipt of 2008–09
TIV may have had direct, adverse effects on A(H1N1)pdm09
illness. Both human and ferret findings from Canada are consistent
with observations elsewhere of enhanced disease following
heterologous influenza challenge in vaccinated swine. Given the
potential implications for informing influenza immuno-epidemi-
ology and public health response to other emerging viruses, these
signals warrant further in-depth evaluation and a search for
possible mechanistic explanations.
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